Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.31 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424176 | 1.00 | MAPK14 (0.37) | MAPK14KDM4EALDH1A1GAAFFAR2 | |
| SCHEMBL421766 | 0.90 | MAPK14 (0.39) | MAPK14FFAR2CNR2 | |
| SCHEMBL421601 | 0.88 | MAPK14 (0.40) | MAPK14GAAHCRTR1HCRTR2RIPK1 | |
| SCHEMBL10109877 | 0.88 | MAPK14 (0.39) | MAPK14ALDH1A1GAAHPGD | |
| SCHEMBL424682 | 0.88 | PTGDR2 (0.38) | MAPK14HCRTR1HCRTR2LMNAHTT | |
| SCHEMBL421761 | 0.85 | PGR (0.39) | MAPK14HCRTR1HCRTR2HSD17B3RIPK1 | |
| SCHEMBL422736 | 0.84 | MAPK14 (0.41) | MAPK14HPGDHCRTR1HCRTR2RIPK1 | |
| SCHEMBL8228075 | 0.83 | KDM4E (0.35) | MAPK14KDM4EALDH1A1GAAFFAR2 | |
| SCHEMBL8239939 | 0.83 | KDM4E (0.35) | MAPK14KDM4EALDH1A1GAAFFAR2 | |
| SCHEMBL14748311 | 0.82 | MAPK14 (0.34) | MAPK14ALDH1A1GAAHPGDHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546438-B2 | Substituted (thiophenyl-carbonyl)imidazolidinones, and use thereof | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| EP-2376482-B1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-03-06 | — | — | EP | disclosed |
| EP-2376482-B1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO KG (DE) | 2013-03-06 | — | — | EP | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2376482-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AiCuris GmbH & Co. KG (DE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010075962-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010075962-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | AICURIS GMBH & CO. KG (DE) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022123-A1 | SUBSTITUTED (THIOPHENYL-CARBONYL)IMIDAZOLIDINONES, AND USE THEREOF | TPMT, MAVS, EIF2AK2 | MAPK14 2294/4885KDM4E 965/4885ALDH1A1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.